A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-07-035725PMID 17264294
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Myelodysplasia: when to treat and how.

  2006cited by this paper
• Decitabine in myelodysplastic syndromes.

  2005cited by this paper
• Tumorigenesis: Flying beneath the radar

  2004cited by this paper
• Direct evidence of leukocyte adhesion in arterioles by angiotensin II.

  2004cited by this paper
• Therapeutic targeting in the estrogen receptor hormonal pathway.

  2004cited by this paper
• Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

  2004cited by this paper
• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

  2004cited by this paper
• Novel therapies for myelodysplastic syndromes

  2004cited by this paper
• Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)

  2004cited by this paper
• Phase I Study Using Alternate Week Administration of the Farnesyl Transferase Inhibitor R115777 (Zarnestra™) in Patients with Myelodysplastic Syndrome.

  2004cited by this paper
• Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

  2004cited by this paper
• A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia.

  2004cited by this paper
• Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

  2004cited by this paper
• Farnesyltransferase inhibitors.

  2004cited by this paper
• Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

  2003cited by this paper
• Long targeting arms do not increase the efficiency of homologous recombination in the beta-globin locus of murine embryonic stem cells.

  2003cited by this paper
• Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

  2003cited by this paper
• Farnesyltransferase inhibitors: promises and realities.

  2002cited by this paper
• Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

  2002cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002cited by this paper
• Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

  2001cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001cited by this paper
• High‐dose chemotherapy in high‐risk myelodysplastic syndrome

  2001cited by this paper
• Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.

  2001cited by this paper
• Farnesyltransferase inhibitors.

  2001cited by this paper
• Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

  2000cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

  1996cited by this paper
• Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia

  1996cited by this paper
• Timed sequential chemotherapy for advanced acute myeloid leukemia.

  1996cited by this paper
• Myelodysplastic syndromes.

  1996cited by this paper
• A Randomized Trial of Hydroxyurea Versus VP 16 in Adult Chronic Myelomonocytic Leukemia

  year unknowncited by this paper
• Myelodysplastic Syndromes

  year unknowncited by this paper

• Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.

  2021cites this paper
• Contemporary risk stratification and treatment of chronic myelomonocytic leukemia.

  2021cites this paper
• Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

  2021cites this paper
• A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.

  2021cites this paper
• Mouse Models of CMML

  2021cites this paper
• Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

  2021cites this paper
• Diagnosis and treatment of chronic myelomonocytic leukemia

  2021cites this paper
• Chronic myelomonocytic leukemia - a review

  2020cites this paper
• Mutation-Driven Therapy in MDS

  2019cites this paper
• Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies

  2019cites this paper
• Current management of patients with chronic myelomonocytic leukemia

  2018cites this paper
• Chronic Myelomonocytic Leukemia: Clinical and Pathologic Features

  2018cites this paper
• Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms

  2018cites this paper
• Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes

  2018cites this paper
• An update on treatment of higher risk myelodysplastic syndromes

  2018cites this paper
• Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia

  2018cites this paper
• Therapy for Chronic Myelomonocytic Leukemia in a New Era

  2017cites this paper
• Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia Short title: Genetic alterations in myelodysplasia with HCT

  2017cites this paper
• Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

  2017cites this paper
• Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?

  2016cites this paper
• Chronic myelomonocytic leukemia: Forefront of the field in 2015.

  2015cites this paper
• Thrombopoiesis‐stimulating agents and myelodysplastic syndromes

  2015cites this paper
• Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions

  2015cites this paper
• Nowe strategie leczenia zespołów mielodysplastycznych wysokiego ryzyka

  2014cites this paper
• Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

  2014cites this paper
• Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.

  2014cites this paper
• MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.

  2014cites this paper
• Current therapy of myelodysplastic syndromes.

  2013cites this paper
• Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.

  2013cites this paper
• Targeting the RAS oncogene

  2013cites this paper
• Management of High-Risk Myelodysplastic Syndrome

  2013cites this paper
• Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?

  2013cites this paper
• Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

  2013cites this paper
• Hypomethylating agents and chemotherapy in MDS.

  2013cites this paper
• Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

  2013cites this paper
• How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.

  2013cites this paper
• The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches

  2013cites this paper
• Signal transduction inhibitors in treatment of myelodysplastic syndromes

  2013cites this paper
• Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

  2012cites this paper
• Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics.

  2012cites this paper
• Current status of allogeneic HST for chronic myelomonocytic leukemia

  2012cites this paper
• Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.

  2012cites this paper
• Lonafarnib for cancer and progeria

  2012cites this paper
• Novel Therapies for Pediatric Cancers

  2012influential citation
• Referenzen des Kompetenznetzes „Akute und chronische Leukämien“

  2012cites this paper
• Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

  2012cites this paper
• Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

  2012cites this paper
• Molecular Targeted Therapies of Medullary Thyroid Carcinoma

  2011cites this paper
• Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group

  2011influential citation
• High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.

  2011cites this paper
• Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions

  2011cites this paper
• Syndromes myélodysplasiques : actualités clinico-biologiques

  2011cites this paper
• Myelodysplastic Syndromes: The Role of Cytogenetic and Molecular Abnormalities for Classification and Risk Assignment

  2011cites this paper
• Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

  2011cites this paper
• myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive

  2011cites this paper
• Incorporating novel agents in the treatment of myelodysplastic syndromes.

  2010cites this paper
• Novel therapies for myelodysplastic syndromes.

  2010cites this paper
• Farnesyltransferase inhibitors: where are we now?

  2010cites this paper
• Medullary thyroid cancer: a promising model for targeted therapy.

  2010cites this paper
• Mediterranean Journal of Hematology and Infectious Diseases New Treatments for Myelodysplastic Syndromes New Treatments for Myelodysplastic Syndromes

  2010cites this paper
• Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents

  2010cites this paper
• Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes

  2010cites this paper
• Pharmacotherapy of myelodysplastic syndromes

  2010cites this paper
• Nuclear inositide signaling in myelodysplastic syndromes

  2010cites this paper
• Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

  2010cites this paper
• Current and Future Management Options for Myelodysplastic Syndromes

  2010cites this paper
• Myelodysplastic Syndromes (MDS)

  2010cites this paper
• Epigenetic causes of apoptosis resistance in cutaneous T-cell lymphomas.

  2010cites this paper
• Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan

  2009cites this paper
• Pharmacotherapy of Hematologic Malignancies with Tipifarnib

  2009cites this paper
• New agents for the treatment of myelodysplastic syndromes

  2009cites this paper
• J-L. Harousseau Tipifarnib in hematologic malignancies

  2009cites this paper
• Tipifarnib in hematologic malignancies

  2009cites this paper
• Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia : a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib ( R 115777 , Zarnestra ) combined with etoposide

  2009cites this paper
• Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine

  2009cites this paper
• Optimal sequencing of treatments for patients with myelodysplastic syndromes

  2009cites this paper
• Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

  2009cites this paper
• Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.

  2009cites this paper
• Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

  2008influential citation
• Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?

  2008cites this paper
• Treatment Strategies in Myelodysplastic Syndromes

  2008cites this paper
• In vitro Effects of the Farnesyltransferase Inhibitor Tipifarnib on Myelodysplastic Syndrome Progenitors

  2008cites this paper
• Targeted Therapy in Myelodysplastic Syndromes

  2008cites this paper
• Towards a Treatment for RAS-MAPK Pathway Disorders

  2008cites this paper
• New therapeutic approaches to acute myeloid leukemia

  2008cites this paper
• Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

  2008cites this paper
• Current treatment options and strategies for myelodysplastic syndromes

  2008cites this paper
• ORIGINAL ARTICLE On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

  2008cites this paper
• Phase II Trialof Tipifarnib asMaintenanceTherapy in First Complete Remission inAdultswithAcuteMyelogenous Leukemia andPoor-Risk Features

  2008cites this paper
• Pediatric developmental therapies: Interesting new drugs now in early-stage clinical trials

  2008cites this paper
• On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

  2008cites this paper
• Possibilities for the treatment of myelodysplastic syndromes and the role of epigenetic therapy.

  2008cites this paper
• Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

  2008cites this paper
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

  2008cites this paper
• Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia

  2008cites this paper
• Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes

  2008cites this paper
• Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

  2008cites this paper
• inhibitor tipifarnib in acute myeloid leukemia A 2-gene classifier for predicting response to the farnesyltransferase

  2008cites this paper
• Are new agents really making a difference in MDS?

  2008cites this paper
• Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification

  2008cites this paper